CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced new pulmonary function data through Week 120 from Study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results